These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Identification of novel VHL target genes and relationship to hypoxic response pathways. Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735 [TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766 [TBL] [Abstract][Full Text] [Related]
5. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720 [TBL] [Abstract][Full Text] [Related]
6. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Rankin EB; Higgins DF; Walisser JA; Johnson RS; Bradfield CA; Haase VH Mol Cell Biol; 2005 Apr; 25(8):3163-72. PubMed ID: 15798202 [TBL] [Abstract][Full Text] [Related]
7. Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1alpha. Sun X; Kanwar JR; Leung E; Vale M; Krissansen GW Gene Ther; 2003 Dec; 10(25):2081-9. PubMed ID: 14595381 [TBL] [Abstract][Full Text] [Related]
8. The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Barry RE; Krek W Trends Mol Med; 2004 Sep; 10(9):466-72. PubMed ID: 15350900 [No Abstract] [Full Text] [Related]
9. Molecular targets from VHL studies into the oxygen-sensing pathway. Maynard MA; Ohh M Curr Cancer Drug Targets; 2005 Aug; 5(5):345-56. PubMed ID: 16101382 [TBL] [Abstract][Full Text] [Related]
10. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Stickle NH; Chung J; Klco JM; Hill RP; Kaelin WG; Ohh M Mol Cell Biol; 2004 Apr; 24(8):3251-61. PubMed ID: 15060148 [TBL] [Abstract][Full Text] [Related]
12. The von Hippel-Lindau tumor suppressor gene. Kondo K; Kaelin WG Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528 [TBL] [Abstract][Full Text] [Related]
13. Activation of hypoxia-induced transcription in normoxia. Hägg M; Wennström S Exp Cell Res; 2005 May; 306(1):180-91. PubMed ID: 15878343 [TBL] [Abstract][Full Text] [Related]
14. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293 [TBL] [Abstract][Full Text] [Related]
15. Deletion of Vhlh in chondrocytes reduces cell proliferation and increases matrix deposition during growth plate development. Pfander D; Kobayashi T; Knight MC; Zelzer E; Chan DA; Olsen BR; Giaccia AJ; Johnson RS; Haase VH; Schipani E Development; 2004 May; 131(10):2497-508. PubMed ID: 15128677 [TBL] [Abstract][Full Text] [Related]
16. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones. Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918 [TBL] [Abstract][Full Text] [Related]
17. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Mack FA; Rathmell WK; Arsham AM; Gnarra J; Keith B; Simon MC Cancer Cell; 2003 Jan; 3(1):75-88. PubMed ID: 12559177 [TBL] [Abstract][Full Text] [Related]
18. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Maynard MA; Ohh M Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728 [TBL] [Abstract][Full Text] [Related]
19. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Pugh CW; Ratcliffe PJ Semin Cancer Biol; 2003 Feb; 13(1):83-9. PubMed ID: 12507560 [TBL] [Abstract][Full Text] [Related]
20. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]